Skip to main content
Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
0.831
-0.049 (-5.57%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Immuron Revenue

Immuron had revenue of 4.18M AUD in the half year ending December 31, 2025, with 77.64% growth. This brings the company's revenue in the last twelve months to 7.48M, up 14.30% year-over-year. In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M with 48.63% growth.

Revenue (ttm)
7.48M AUD
Revenue Growth
+14.30%
P/S Ratio
1.48
Revenue / Employee
1,068,145 AUD
Employees
7
Market Cap
7.37M USD

Revenue Chart

* This company reports financials in AUD.

History

Fiscal Year End Revenue Change Growth
Jun 30, 20257.29M2.38M48.63%
Jun 30, 20244.90M3.10M171.67%
Jun 30, 20231.80M1.04M135.85%
Jun 30, 2022765.19K619.42K424.91%
Jun 30, 2021145.78K-2.37M-94.21%
Jun 30, 2020 Pro Pro Pro
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Evogene 8.02M
Bolt Biotherapeutics 5.20M
Addex Therapeutics 198.82K
Kiora Pharmaceuticals 20.00K
Alaunos Therapeutics 6.00K
Creative Medical Technology Holdings 6.00K
Pulmatrix 3.00K
Ernexa Therapeutics 1,000.00
Revenue Rankings

IMRN News

More News